Serdar Kabataş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Serdar Kabataş has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Erdinç Civelek
Sağlık Bilimleri Üniversitesi, Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye
17 shared publications - Furkan Diren
Sağlık Bilimleri Üniversitesi, Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye
10 shared publications - Osman Boyalı
Sağlık Bilimleri Üniversitesi, Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye
10 shared publications - Eyüp Can Savrunlu
University of Health Sciences Türkiye, Gaziosmanpaşa Training and Research Hospital, Clinic of Neurosurgery, İstanbul, Türkiye
7 shared publications Erdinç Civelek
6 shared publicationsErdal Karaöz
5 shared publications
Latest Publications
- Open Access
- 9 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Critical Care Medicine
- Vol. 14 (4)
Efficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury
BACKGROUND Traumatic brain injury (TBI) is a significant public health issue, leading to long-term neurological impairments. Current treatments offer limited recovery, particularly in restoring lost functions. Mesenchymal stem cell-derived exosomes (MSCdE) have shown potential for promoting neuroprotection and regeneration. This study evaluates the safety and efficacy of MSCdE therapy in TBI patients. AIM To evaluate the safety and efficacy of MSCdE therapy in TBI patients. METHODS Five patients (mean age 27.00 ± 4.06 years) with TBI from combat injuries were treated with six rounds of MSCdE therapy (3 mL intrathecally and 3 mL intramuscularly per round). The patients were followed for one year. Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0), and functional outcomes were evaluated with the functional independence measure (FIM), Modified Ashworth Scale (MAS), and Karnofsky Performance Scale (KPS). RESULTS No serious adverse events occurred, and only mild side effects [subfebrile fever (37.5-37.9 ℃), pain] were reported (CTCAE Grade 1). FIM motor scores improved significantly (46.20 ± 16.39 to 64.20 ± 18.20, P < 0.01), and FIM cognitive scores also showed significant improvement (30.60 ± 4.56 to 34.00 ± 1.41, P < 0.001). While MAS scores improved (right/left: 4.60/3.60 to 2.20/1.60), these changes were not statistically significant (P > 0.05), possibly due to low baseline spasticity. KPS scores significantly improved (46.00 ± 11.40 to 72.00 ± 8.37, P < 0.001), indicating enhanced overall functional status and quality of life. CONCLUSION MSCdE therapy is safe and effective in improving motor function, cognition, and quality of life in TBI patients. Larger, controlled trials are needed to further validate these findings and optimize MSCdE therapy for TBI treatment.
- 9 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Critical Care Medicine
- Vol. 14 (4)
Open AccessEfficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury
BACKGROUND Traumatic brain injury (TBI) is a significant public health issue, leading to long-term neurological impairments. Current treatments offer limited recovery, particularly in restoring lost functions. Mesenchymal stem cell-derived exosomes (MSCdE) have shown potential for promoting neuroprotection and regeneration. This study evaluates the safety and efficacy of MSCdE therapy in TBI patients. AIM To evaluate the safety and efficacy of MSCdE therapy in TBI patients. METHODS Five patients (mean age 27.00 ± 4.06 years) with TBI from combat injuries were treated with six rounds of MSCdE therapy (3 mL intrathecally and 3 mL intramuscularly per round). The patients were followed for one year. Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0), and functional outcomes were evaluated with the functional independence measure (FIM), Modified Ashworth Scale (MAS), and Karnofsky Performance Scale (KPS). RESULTS No serious adverse events occurred, and only mild side effects [subfebrile fever (37.5-37.9 ℃), pain] were reported (CTCAE Grade 1). FIM motor scores improved significantly (46.20 ± 16.39 to 64.20 ± 18.20, P < 0.01), and FIM cognitive scores also showed significant improvement (30.60 ± 4.56 to 34.00 ± 1.41, P < 0.001). While MAS scores improved (right/left: 4.60/3.60 to 2.20/1.60), these changes were not statistically significant (P > 0.05), possibly due to low baseline spasticity. KPS scores significantly improved (46.00 ± 11.40 to 72.00 ± 8.37, P < 0.001), indicating enhanced overall functional status and quality of life. CONCLUSION MSCdE therapy is safe and effective in improving motor function, cognition, and quality of life in TBI patients. Larger, controlled trials are needed to further validate these findings and optimize MSCdE therapy for TBI treatment.
- Open Access
- 26 May 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 17 (5) , 101675
Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study
BACKGROUND Traumatic spinal cord injury (SCI) is a life-altering condition that results in long-term complications, including progressive neurodegeneration and cord atrophy. It presents a significant unmet medical need with extensive social and economic burdens. AIM To evaluate the safety and preliminary efficacy of allogeneic mesenchymal stem cells derived from Wharton’s jelly (WJ-MSCs) in patients with chronic complete SCI. The primary objective was to assess whether WJ-MSCs could facilitate neurological recovery and improve the quality of life in this patient population. METHODS This open-label, multicenter phase I study investigated the effects of administering WJ-MSCs via three delivery routes: Intrathecal (for localized spinal targeting); intramuscular (for targeting end organ); and intravenous (for systemic immunomodulation). While all three routes were used concurrently to enhance therapeutic synergy, neurological, sensory, and functional scales were used to assess overall efficacy. Participants with chronic SCI (duration of at least 6 months) who had significant impairment and disability were eligible for inclusion. WJ-MSCs were administered twice monthly for 2 months, with each route receiving a dose of 1 × 106 cells/kg. Patients were closely monitored for 1 year following treatment. RESULTS At baseline, participants displayed considerable functional deficits, as indicated by the following scores: Functional independence measure of 77.5 ± 2.26; Modified Ashworth Scale of 15.83 ± 4.83; American Spinal Injury Association (ASIA) Motor score of 1.67 ± 2.66; ASIA Light Touch and Pin-Prick scores of 62 ± 18.42 each; Wexner Incontinence Score of 20; and Qualiveen Short Form, a validated questionnaire specifically designed to assess the impact of urinary dysfunction on quality of life in individuals with SCI, score of 32. Following WJ-MSC therapy, significant improvements were observed in all neurological functions over the 1-year follow-up. Notably, the ASIA Motor score improved significantly (χ 2 = 23.938, P < 0.001), and Qualiveen Short Form scores demonstrated a substantial enhancement in quality of life (z = -2.214, P < 0.05). CONCLUSION This phase I study, conducted without a control group, suggests that the administration of WJ-MSCs through multiple routes is both safe and potentially effective in patients with chronic complete SCI. However, the observed neurological improvements cannot be solely attributed to WJ-MSC therapy, as concurrent pharmacological and rehabilitative interventions were not controlled. These findings indicated that WJ-MSC therapy may offer a promising approach for enhancing neurological function and quality of life in this challenging patient population. Further research with larger cohorts and extended follow-up is necessary to validate these preliminary results.
- 26 May 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 17 (5) , 101675
Open AccessMultiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study
BACKGROUND Traumatic spinal cord injury (SCI) is a life-altering condition that results in long-term complications, including progressive neurodegeneration and cord atrophy. It presents a significant unmet medical need with extensive social and economic burdens. AIM To evaluate the safety and preliminary efficacy of allogeneic mesenchymal stem cells derived from Wharton’s jelly (WJ-MSCs) in patients with chronic complete SCI. The primary objective was to assess whether WJ-MSCs could facilitate neurological recovery and improve the quality of life in this patient population. METHODS This open-label, multicenter phase I study investigated the effects of administering WJ-MSCs via three delivery routes: Intrathecal (for localized spinal targeting); intramuscular (for targeting end organ); and intravenous (for systemic immunomodulation). While all three routes were used concurrently to enhance therapeutic synergy, neurological, sensory, and functional scales were used to assess overall efficacy. Participants with chronic SCI (duration of at least 6 months) who had significant impairment and disability were eligible for inclusion. WJ-MSCs were administered twice monthly for 2 months, with each route receiving a dose of 1 × 106 cells/kg. Patients were closely monitored for 1 year following treatment. RESULTS At baseline, participants displayed considerable functional deficits, as indicated by the following scores: Functional independence measure of 77.5 ± 2.26; Modified Ashworth Scale of 15.83 ± 4.83; American Spinal Injury Association (ASIA) Motor score of 1.67 ± 2.66; ASIA Light Touch and Pin-Prick scores of 62 ± 18.42 each; Wexner Incontinence Score of 20; and Qualiveen Short Form, a validated questionnaire specifically designed to assess the impact of urinary dysfunction on quality of life in individuals with SCI, score of 32. Following WJ-MSC therapy, significant improvements were observed in all neurological functions over the 1-year follow-up. Notably, the ASIA Motor score improved significantly (χ 2 = 23.938, P < 0.001), and Qualiveen Short Form scores demonstrated a substantial enhancement in quality of life (z = -2.214, P < 0.05). CONCLUSION This phase I study, conducted without a control group, suggests that the administration of WJ-MSCs through multiple routes is both safe and potentially effective in patients with chronic complete SCI. However, the observed neurological improvements cannot be solely attributed to WJ-MSC therapy, as concurrent pharmacological and rehabilitative interventions were not controlled. These findings indicated that WJ-MSC therapy may offer a promising approach for enhancing neurological function and quality of life in this challenging patient population. Further research with larger cohorts and extended follow-up is necessary to validate these preliminary results.
- Open Access
- 14 May 2025
- Published by Galenos Yayinevi in Turkish Journal of Anaesthesiology and Reanimation
- Vol. 53 (5) , 233-241
Retrospective Clinical and Radiological Comparison of Intradiscal Ozone and Ozone + PRP Therapy Results in Patients with Intervertebral Disc Degeneration
Retrospective Clinical and Radiological Comparison of Intradiscal Ozone and Ozone + PRP Therapy Results in Patients with Intervertebral Disc Degeneration - Turkish Journal of Anaesthesiology and Reanimation
- 14 May 2025
- Published by Galenos Yayinevi in Turkish Journal of Anaesthesiology and Reanimation
- Vol. 53 (5) , 233-241
Open AccessRetrospective Clinical and Radiological Comparison of Intradiscal Ozone and Ozone + PRP Therapy Results in Patients with Intervertebral Disc Degeneration
Retrospective Clinical and Radiological Comparison of Intradiscal Ozone and Ozone + PRP Therapy Results in Patients with Intervertebral Disc Degeneration - Turkish Journal of Anaesthesiology and Reanimation
- Open Access
- 20 March 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (1) , 95857
Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation
BACKGROUND Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with multifaceted origins. In recent studies, neuroinflammation and immune dysregulation have come to the forefront in its pathogenesis. There are studies suggesting that stem cell therapy may be effective in the treatment of ASD. AIM To evolve the landscape of ASD treatment, focusing on the potential benefits and safety of stem cell transplantation. METHODS A detailed case report is presented, displaying the positive outcomes observed in a child who underwent intrathecal and intravenous Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) transplantation combined with neurorehabilitation. RESULTS The study demonstrates a significant improvement in the child’s functional outcomes (Childhood Autism Rating Scale, Denver 2 Developmental Screening Test), especially in language and gross motor skills. No serious side effects were encountered during the 2-year follow-up. CONCLUSION The findings support the safety and effectiveness of WJ-MSC transplantation in managing ASD.
- 20 March 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (1) , 95857
Open AccessAdvances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation
BACKGROUND Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with multifaceted origins. In recent studies, neuroinflammation and immune dysregulation have come to the forefront in its pathogenesis. There are studies suggesting that stem cell therapy may be effective in the treatment of ASD. AIM To evolve the landscape of ASD treatment, focusing on the potential benefits and safety of stem cell transplantation. METHODS A detailed case report is presented, displaying the positive outcomes observed in a child who underwent intrathecal and intravenous Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) transplantation combined with neurorehabilitation. RESULTS The study demonstrates a significant improvement in the child’s functional outcomes (Childhood Autism Rating Scale, Denver 2 Developmental Screening Test), especially in language and gross motor skills. No serious side effects were encountered during the 2-year follow-up. CONCLUSION The findings support the safety and effectiveness of WJ-MSC transplantation in managing ASD.
- Open Access
Concurrent Oncolysis and Neurolesion Repair by Dual Gene-Engineered hNSCs in an Experimental Model of Intraspinal Cord Glioblastoma
Intramedullary spinal cord glioblastoma (ISCG) is lethal due to lack of effective treatment. We previously established a rat C6-ISCG model and the antitumor effect of F3.CD-TK, an hNSC line expressing CD and TK, via producing cytocidal 5FU and GCV-TP. However, the neurotherapeutic potential of this hNSC approach has remained uninvestigated. Here for the first time, cultured F3.CD-TK cells were found to have a markedly higher oncolytic effect, which was GJIC-dependent, and BDNF expression but less VEGF secretion than F3.CD. In Rowett athymic rats, F3.CD-TK (1.5 × 106 cells/10 µL × 2), injected near C6-ISCG (G55 seeding 7 days earlier: 10 K/each) and followed by q.d. (×5/each repeat; i.p.) of 5FC (500 mg/kg/5 mL/day) and GCV (25 mg/kg/1 mL/day), robustly mitigated cardiorespiratory, locomotor, and sensory deficits to improve neurofunction and overall survival compared to animals receiving either F3.CD or F3.CD-TK+F3.CD debris formula. The F3.CD-TK regimen exerted greater tumor penetration and neural inflammation/immune modulation, reshaped C6-ISCG topology to increase the tumor’s surface area/volume ratio to spare/repair host axons (e.g., vGlut1+ neurites), and had higher post-prodrug donor self-clearance. The multimodal data and mechanistic leads from this proof-of-principle study suggest that the overall stronger anti-ISCG benefit of our hNSC-based GDEPT is derived from its concurrent oncolytic and neurotherapeutic effects.
Open AccessConcurrent Oncolysis and Neurolesion Repair by Dual Gene-Engineered hNSCs in an Experimental Model of Intraspinal Cord Glioblastoma
Intramedullary spinal cord glioblastoma (ISCG) is lethal due to lack of effective treatment. We previously established a rat C6-ISCG model and the antitumor effect of F3.CD-TK, an hNSC line expressing CD and TK, via producing cytocidal 5FU and GCV-TP. However, the neurotherapeutic potential of this hNSC approach has remained uninvestigated. Here for the first time, cultured F3.CD-TK cells were found to have a markedly higher oncolytic effect, which was GJIC-dependent, and BDNF expression but less VEGF secretion than F3.CD. In Rowett athymic rats, F3.CD-TK (1.5 × 106 cells/10 µL × 2), injected near C6-ISCG (G55 seeding 7 days earlier: 10 K/each) and followed by q.d. (×5/each repeat; i.p.) of 5FC (500 mg/kg/5 mL/day) and GCV (25 mg/kg/1 mL/day), robustly mitigated cardiorespiratory, locomotor, and sensory deficits to improve neurofunction and overall survival compared to animals receiving either F3.CD or F3.CD-TK+F3.CD debris formula. The F3.CD-TK regimen exerted greater tumor penetration and neural inflammation/immune modulation, reshaped C6-ISCG topology to increase the tumor’s surface area/volume ratio to spare/repair host axons (e.g., vGlut1+ neurites), and had higher post-prodrug donor self-clearance. The multimodal data and mechanistic leads from this proof-of-principle study suggest that the overall stronger anti-ISCG benefit of our hNSC-based GDEPT is derived from its concurrent oncolytic and neurotherapeutic effects.
- Open Access
- 26 June 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 16 (6) , 641-655
Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study
BACKGROUND Traumatic brain injury (TBI) is characterized by a disruption in the normal function of the brain due to an injury following a trauma, which can potentially cause severe physical, cognitive, and emotional impairment. Stem cell transplantation has evolved as a novel treatment modality in the management of TBI, as it has the potential to arrest the degeneration and promote regeneration of new cells in the brain. Wharton’s Jelly-derived mesenchymal stem cells (WJ-MSCs) have recently shown beneficial effects in the functional recovery of neurological deficits. AIM To evaluate the safety and efficiency of MSC therapy in TBI. METHODS We present 6 patients, 4 male and 2 female aged between 21 and 27 years who suffered a TBI. These 6 patients underwent 6 doses of intrathecal, intramuscular (i.m.) and intravenous transplantation of WJ-MSCs at a target dose of 1 × 106/kg for each application route. Spasticity was assessed using the Modified Ashworth scale (MAS), motor function according to the Medical Research Council Muscle Strength Scale, quality of life was assessed by the Functional Independence Measure (FIM) scale and Karnofsky Performance Status scale. RESULTS Our patients showed only early, transient complications, such as subfebrile fever, mild headache, and muscle pain due to i.m. injection, which resolved within 24 h. During the one year follow-up, no other safety issues or adverse events were reported. These 6 patients showed improvements in their cognitive abilities, muscle spasticity, muscle strength, performance scores and fine motor skills when compared before and after the intervention. MAS values, which we used to assess spasticity, were observed to statistically significantly decrease for both left and right sides (P < 0.001). The FIM scale includes both motor scores (P < 0.05) and cognitive scores (P < 0.001) and showed a significant increase in pretest posttest analyses. The difference observed in the participants’ Karnofsky Performance Scale values pre and post the intervention was statistically significant (P < 0.001). CONCLUSION This study showed that cell transplantation has a safe, effective and promising future in the management of TBI.
- 26 June 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 16 (6) , 641-655
Open AccessSafety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study
BACKGROUND Traumatic brain injury (TBI) is characterized by a disruption in the normal function of the brain due to an injury following a trauma, which can potentially cause severe physical, cognitive, and emotional impairment. Stem cell transplantation has evolved as a novel treatment modality in the management of TBI, as it has the potential to arrest the degeneration and promote regeneration of new cells in the brain. Wharton’s Jelly-derived mesenchymal stem cells (WJ-MSCs) have recently shown beneficial effects in the functional recovery of neurological deficits. AIM To evaluate the safety and efficiency of MSC therapy in TBI. METHODS We present 6 patients, 4 male and 2 female aged between 21 and 27 years who suffered a TBI. These 6 patients underwent 6 doses of intrathecal, intramuscular (i.m.) and intravenous transplantation of WJ-MSCs at a target dose of 1 × 106/kg for each application route. Spasticity was assessed using the Modified Ashworth scale (MAS), motor function according to the Medical Research Council Muscle Strength Scale, quality of life was assessed by the Functional Independence Measure (FIM) scale and Karnofsky Performance Status scale. RESULTS Our patients showed only early, transient complications, such as subfebrile fever, mild headache, and muscle pain due to i.m. injection, which resolved within 24 h. During the one year follow-up, no other safety issues or adverse events were reported. These 6 patients showed improvements in their cognitive abilities, muscle spasticity, muscle strength, performance scores and fine motor skills when compared before and after the intervention. MAS values, which we used to assess spasticity, were observed to statistically significantly decrease for both left and right sides (P < 0.001). The FIM scale includes both motor scores (P < 0.05) and cognitive scores (P < 0.001) and showed a significant increase in pretest posttest analyses. The difference observed in the participants’ Karnofsky Performance Scale values pre and post the intervention was statistically significant (P < 0.001). CONCLUSION This study showed that cell transplantation has a safe, effective and promising future in the management of TBI.
- 26 December 2022
- Published by Galenos Yayinevi in Journal of Academic Research in Medicine
- Vol. 12 (3) , 124-129
Factors Associated with Clinical Outcomes in Spontaneous Subarachnoid Hemorrhage
- 26 December 2022
- Published by Galenos Yayinevi in Journal of Academic Research in Medicine
- Vol. 12 (3) , 124-129
Factors Associated with Clinical Outcomes in Spontaneous Subarachnoid Hemorrhage
- 15 December 2022
- Published by Hatay Mustafa Kemal University Faculty of Medicine in Mustafa Kemal Üniversitesi Tıp Dergisi
- Vol. 13 (47) , 361-369
Ekstrakraniyal uzanımı olan menengiomların tedavisinin zorlukları: Klinik çalışma
Objective: Surgical treatment of extracranial meningiomas is challenging. In this study, we present an illustrated case series to share our experience in the treatment of meningiomas with extracranial extension. Method: We retrospectively reviewed the data of 11 patients with meningiomas who underwent surgical treatment between 2008 and 2020. The intracranial and extracranial components were radiologically and intraoperatively confirmed for all patients. Results: The patients included seven men and four women with a mean age of 55.4 years. Most patients presented with facial disfigurement or asymmetrical skull growth. The most common symptom at presentation was headache. The most common location of the meningiomas was the frontal region and those of extracranial growth were the paranasal sinuses and parietal bone invasion. We recognized two distinct modalities of bone destruction: hyperostosis (n=3) and osteolysis (n=8). Pathological investigation revealed atypical features in six patients. Preoperative embolization was attempted in four patients but it proved to be difficult; proper embolization could be achieved only in one patient. The most commonly encountered challenges during surgery were large calvarial and cranial base defects due to bone erosion, dural defects, and managing the superior sagittal sinus with parietal tumors. Excessive blood loss was also of particular concern, which was managed using simple scalp clips, intraoperative transfusion, and other conservative approaches of tumor extensions into paranasal sinuses. No perioperative mortality occurred. Calvarial reconstruction was performed with polymethyl methacrylate cement where needed. Conclusion: Meningiomas with extracranial extension are surgically challenging but treatable. It contains fine neurosurgical trics in its treatment and follow-up.
- 15 December 2022
- Published by Hatay Mustafa Kemal University Faculty of Medicine in Mustafa Kemal Üniversitesi Tıp Dergisi
- Vol. 13 (47) , 361-369
Ekstrakraniyal uzanımı olan menengiomların tedavisinin zorlukları: Klinik çalışma
Objective: Surgical treatment of extracranial meningiomas is challenging. In this study, we present an illustrated case series to share our experience in the treatment of meningiomas with extracranial extension. Method: We retrospectively reviewed the data of 11 patients with meningiomas who underwent surgical treatment between 2008 and 2020. The intracranial and extracranial components were radiologically and intraoperatively confirmed for all patients. Results: The patients included seven men and four women with a mean age of 55.4 years. Most patients presented with facial disfigurement or asymmetrical skull growth. The most common symptom at presentation was headache. The most common location of the meningiomas was the frontal region and those of extracranial growth were the paranasal sinuses and parietal bone invasion. We recognized two distinct modalities of bone destruction: hyperostosis (n=3) and osteolysis (n=8). Pathological investigation revealed atypical features in six patients. Preoperative embolization was attempted in four patients but it proved to be difficult; proper embolization could be achieved only in one patient. The most commonly encountered challenges during surgery were large calvarial and cranial base defects due to bone erosion, dural defects, and managing the superior sagittal sinus with parietal tumors. Excessive blood loss was also of particular concern, which was managed using simple scalp clips, intraoperative transfusion, and other conservative approaches of tumor extensions into paranasal sinuses. No perioperative mortality occurred. Calvarial reconstruction was performed with polymethyl methacrylate cement where needed. Conclusion: Meningiomas with extracranial extension are surgically challenging but treatable. It contains fine neurosurgical trics in its treatment and follow-up.
- Open Access
- 15 September 2022
- Published by Nervous System Surgery Society in Sinir Sistemi Cerrahisi Dergisi
- Vol. 8 (2) , 73-77
Nöroşirurjide Yeni Nesil Dura Sızdırmazlık Sağlayıcı Yama (Hemopatch®) ile Klinik Deneyimimiz
Cerebrospinal fluid (CSF) fistula is an important complication in neurosurgery. A literature review was performed with the use of Hemopatch® in cranial surgery together with fibrin glue. Early and late postoperative results of 4 patients who were operated for an intracranial mass and used Hemopatch® with fibrin glue in the dural closure of CSF leak stage were evaluated. The mean age of the patients was 62.25 ± 10.49 years and the mean follow-up period was 16.25 ± 3.27 weeks. All of the patients who used fibrin glue Hemopatch® consisted of patients who had undergone cranial surgery (75% was pterional craniotomy, 25% was retrosigmoid craniotomy). Cerebrospinal Fluid (CSF) leakage occurred in the early post-operative period in 1 patient who underwent Hemopatch® by completely removing the dural layer due to extensive dural invasion and performing duraplasty with fascia after the follow-up. Hemopatch was applied and CSF leakage was not observed in the other 3 patients with small dural defects. In conclusion, we first demonstrated the feasibility and safety of using Hemopatch® as a dural sealant in fibrin glued cranial surgery.
- 15 September 2022
- Published by Nervous System Surgery Society in Sinir Sistemi Cerrahisi Dergisi
- Vol. 8 (2) , 73-77
Open AccessNöroşirurjide Yeni Nesil Dura Sızdırmazlık Sağlayıcı Yama (Hemopatch®) ile Klinik Deneyimimiz
Cerebrospinal fluid (CSF) fistula is an important complication in neurosurgery. A literature review was performed with the use of Hemopatch® in cranial surgery together with fibrin glue. Early and late postoperative results of 4 patients who were operated for an intracranial mass and used Hemopatch® with fibrin glue in the dural closure of CSF leak stage were evaluated. The mean age of the patients was 62.25 ± 10.49 years and the mean follow-up period was 16.25 ± 3.27 weeks. All of the patients who used fibrin glue Hemopatch® consisted of patients who had undergone cranial surgery (75% was pterional craniotomy, 25% was retrosigmoid craniotomy). Cerebrospinal Fluid (CSF) leakage occurred in the early post-operative period in 1 patient who underwent Hemopatch® by completely removing the dural layer due to extensive dural invasion and performing duraplasty with fascia after the follow-up. Hemopatch was applied and CSF leakage was not observed in the other 3 patients with small dural defects. In conclusion, we first demonstrated the feasibility and safety of using Hemopatch® as a dural sealant in fibrin glued cranial surgery.
- Open Access
- 15 September 2022
- Published by Nervous System Surgery Society in Sinir Sistemi Cerrahisi Dergisi
- Vol. 8 (2) , 60-67
Evaluation of Serum Superoxide Dismutase Levels in Lumbar Degenerative Spinal Diseases: A Prospective Meta-analysis
Background: The aim of this study was to evaluate the correlation between serum superoxide dismutase (SOD) enzyme levels and lumbar degenerative spinal diseases (LDSD).Materials and Methods: Ninety-four patients with LDSD and 64 patients without LDSD were investigated. Human SOD ELISA kits were used to measure the amount of enzymes in the samples. Serum SOD enzyme levels were determined by Student-t and Mann Whitney-U tests to determine differences between groups.Results: The patient group was classified according to the characteristics of the disease, clinical symptoms, Visual Analog Scale (VAS) values, and Oswestry Disability Index (ODI) scores. Along with these parameters, serum SOD levels were evaluated statistically. There was no statistically significant difference in serum SOD levels in both groups. However, serum SOD levels were relatively lower in the patient group (p>0.05).Conclusions: Our study could supply objective value for future researchers investigating specific lumbar diseases, should they attempt to find a serum biomarker for the disease. More studies with an increasing number of patients are needed to support the results of our study. Doing so may offer more specific insights on the mechanisms of LDSD and its features, which could contribute to the literature.
- 15 September 2022
- Published by Nervous System Surgery Society in Sinir Sistemi Cerrahisi Dergisi
- Vol. 8 (2) , 60-67
Open AccessEvaluation of Serum Superoxide Dismutase Levels in Lumbar Degenerative Spinal Diseases: A Prospective Meta-analysis
Background: The aim of this study was to evaluate the correlation between serum superoxide dismutase (SOD) enzyme levels and lumbar degenerative spinal diseases (LDSD).Materials and Methods: Ninety-four patients with LDSD and 64 patients without LDSD were investigated. Human SOD ELISA kits were used to measure the amount of enzymes in the samples. Serum SOD enzyme levels were determined by Student-t and Mann Whitney-U tests to determine differences between groups.Results: The patient group was classified according to the characteristics of the disease, clinical symptoms, Visual Analog Scale (VAS) values, and Oswestry Disability Index (ODI) scores. Along with these parameters, serum SOD levels were evaluated statistically. There was no statistically significant difference in serum SOD levels in both groups. However, serum SOD levels were relatively lower in the patient group (p>0.05).Conclusions: Our study could supply objective value for future researchers investigating specific lumbar diseases, should they attempt to find a serum biomarker for the disease. More studies with an increasing number of patients are needed to support the results of our study. Doing so may offer more specific insights on the mechanisms of LDSD and its features, which could contribute to the literature.